Interim Chief Financial Officer
Kevin Gordon, Interim Chief Financial Officer, at Worldwide Clinical Trials is an accomplished executive with over 30 years of leadership experience in healthcare and life sciences. He currently serves on the board of directors for Progyny, Inc., a leading fertility benefits management company, where he has been a board member since its IPO in October 2019. He previously held a six-year board position with Veracyte, Inc., a global leader in genomic diagnostics. Kevin has also advised 3i Group’s North American healthcare portfolio, contributing to the success of companies such as Q Holdco Limited, Sanisure, and Cirtec Medical Corp.
Submit an RFP. Ask a Question
In his executive roles, Kevin has been instrumental in guiding companies through significant milestones, including leading the 2018 IPO of Liquidia Technologies Inc., where he served as President and Chief Financial Officer. At Quintiles (now IQVIA), a global leader in clinical trials and pharmaceutical consulting, he played a pivotal role as Chief Operating Officer and Chief Financial Officer, overseeing the company’s successful 2013 IPO. Earlier in his career, he served as CFO and EVP at Teleflex Incorporated, leading corporate development for a decade before becoming CFO.
Kevin began his professional journey at KPMG LLP after earning a B.S. in Accounting from the University of Connecticut, and he has continued to build a distinguished career characterized by his strategic insight, financial acumen, and leadership in driving organizational growth.